JP2015067593A - Liquid composition containing useful component in turmeric and turmeric pigment - Google Patents
Liquid composition containing useful component in turmeric and turmeric pigment Download PDFInfo
- Publication number
- JP2015067593A JP2015067593A JP2013205631A JP2013205631A JP2015067593A JP 2015067593 A JP2015067593 A JP 2015067593A JP 2013205631 A JP2013205631 A JP 2013205631A JP 2013205631 A JP2013205631 A JP 2013205631A JP 2015067593 A JP2015067593 A JP 2015067593A
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- bisaclone
- turmeric
- hangover
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 239000007788 liquid Substances 0.000 title claims abstract description 50
- 235000003373 curcuma longa Nutrition 0.000 title description 31
- 235000003392 Curcuma domestica Nutrition 0.000 title description 26
- 235000013976 turmeric Nutrition 0.000 title description 26
- 244000008991 Curcuma longa Species 0.000 title description 23
- 239000000049 pigment Substances 0.000 title description 14
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 47
- 206010019133 Hangover Diseases 0.000 claims abstract description 43
- 208000024891 symptom Diseases 0.000 claims abstract description 42
- 235000012754 curcumin Nutrition 0.000 claims abstract description 23
- 229940109262 curcumin Drugs 0.000 claims abstract description 23
- 239000004148 curcumin Substances 0.000 claims abstract description 23
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- 239000003112 inhibitor Substances 0.000 claims description 12
- 229940052016 turmeric extract Drugs 0.000 claims description 11
- 235000020240 turmeric extract Nutrition 0.000 claims description 11
- 239000008513 turmeric extract Substances 0.000 claims description 11
- 206010028813 Nausea Diseases 0.000 claims description 7
- 206010025482 malaise Diseases 0.000 claims description 7
- 230000008693 nausea Effects 0.000 claims description 7
- 206010000059 abdominal discomfort Diseases 0.000 claims description 6
- 230000035807 sensation Effects 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 12
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 229930014626 natural product Natural products 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract description 3
- QJOWFYQIUZMPRY-NEBZKDRISA-N (6s)-6-[(1r,4s,5s)-4,5-dihydroxy-4-methylcyclohex-2-en-1-yl]-2-methylhept-2-en-4-one Chemical compound CC(C)=CC(=O)C[C@H](C)[C@H]1C[C@H](O)[C@@](C)(O)C=C1 QJOWFYQIUZMPRY-NEBZKDRISA-N 0.000 abstract 1
- MOTTXBGNWKHMBK-UHFFFAOYSA-N Bisacurone Natural products CC(CC(=O)C=C(C)C)C1CCC(C)(O)C(O)C1 MOTTXBGNWKHMBK-UHFFFAOYSA-N 0.000 abstract 1
- QJOWFYQIUZMPRY-UHFFFAOYSA-N Bisacurone A Natural products CC(C)=CC(=O)CC(C)C1CC(O)C(C)(O)C=C1 QJOWFYQIUZMPRY-UHFFFAOYSA-N 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 33
- 235000013361 beverage Nutrition 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 241000196324 Embryophyta Species 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 244000163122 Curcuma domestica Species 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- -1 acidulants Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 235000003398 Curcuma aromatica Nutrition 0.000 description 1
- 241000963421 Curcuma kwangsiensis Species 0.000 description 1
- 235000003397 Curcuma kwangsiensis Nutrition 0.000 description 1
- 240000005629 Curcuma phaeocaulis Species 0.000 description 1
- 235000003391 Curcuma phaeocaulis Nutrition 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 1
- 244000164418 Curcuma xanthorrhiza Species 0.000 description 1
- 235000003393 Curcuma xanthorrhiza Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、二日酔いの症状を抑制することが可能な、ビサクロン及びウコン色素を含有する液状組成物に関する。 The present invention relates to a liquid composition containing bisaclone and a turmeric pigment capable of suppressing the symptoms of hangover.
ウコン(ショウガ科ウコン,Curcuma longa LINNE)は東南アジアを中心に、世界中の熱帯・亜熱帯地域で栽培されるショウガ科ウコン属の薬用植物である。 Turmeric (Curcuma longa LINNE) is a medicinal plant belonging to the genus Turmeric in the tropical and subtropical regions of the world, mainly in Southeast Asia.
ウコンの根茎には3〜5%のクルクミン(黄色色素)が含有される。ウコン抽出物及びクルクミンには様々な有用性が知られている。例えば非特許文献1ではウコン抽出物含有飲料はアルコールと一緒に摂取することにより、アルコール本来の「酔い」を適度に発現させながら、悪酔いを防止する作用を有することが示唆されている。 Turmeric rhizomes contain 3-5% curcumin (yellow pigment). Various utilities are known for turmeric extract and curcumin. For example, Non-Patent Document 1 suggests that a turmeric extract-containing beverage has an action of preventing sickness while appropriately expressing the “sickness” inherent in alcohol by ingesting together with alcohol.
特許文献1にはウコン又はその抽出物を、オウバク又はその抽出物、オウレン又はその抽出物及びショウキョウ又はその抽出物と組み合わせて含有する、二日酔いの予防・治療のための医薬用組成物が開示されている。 Patent Document 1 discloses a pharmaceutical composition for the prevention and treatment of hangover, comprising turmeric or an extract thereof in combination with duck or an extract thereof, oren or an extract thereof and ginger or an extract thereof. Has been.
特許文献2にはウコンを、ニンニク加工物とともに含有する、アルコール摂取後のムカツキ、吐き気、二日酔い等の不快な症状を改善する作用を有する医薬組成物が開示されている。 Patent Document 2 discloses a pharmaceutical composition containing turmeric together with a processed garlic product and having an action of improving unpleasant symptoms such as irritations after drinking alcohol, nausea, and hangover.
一方、依然として二日酔いの症状に対して有効な治療剤及び予防剤が求められており、しかも食経験が豊富で安全性の高い天然由来の成分を有効成分とする治療剤及び予防剤が求められている。 On the other hand, there is still a need for an effective therapeutic agent and preventive agent for hangover symptoms, and there is a need for a therapeutic agent and prophylactic agent that has abundant dietary experience and a highly safe naturally-derived component as an active ingredient. Yes.
本発明は、食経験が豊富な安全性の高い食品素材から得られる天然化合物を有効成分とする、二日酔いの症状を抑制することが可能な組成物を提供することを目的とする。 An object of this invention is to provide the composition which can suppress the symptom of a hangover which uses the natural compound obtained from the food material with abundant food experience with high safety as an active ingredient.
本発明者らは、上記課題を解決するために鋭意研究した結果、ウコン抽出物に含まれるビサクロンが二日酔い症状の抑制作用を有することを見出し、本発明を完成させるに至った。 As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that bisaclone contained in the turmeric extract has an action to suppress hangover symptoms, and have completed the present invention.
すなわち、本発明は、以下の特徴を有する。
[1] ビサクロンとウコン色素を含む、pHが2.3以上、3.2未満の範囲にある液状組成物であって、一回の経口摂取量当たり、ビサクロンを0.15mg以上含有する液状組成物。
[2] ビサクロンがウコン抽出物に由来する、[1]の液状組成物。
[3] 飲食品又は医薬品である、[1]又は[2]の液状組成物。
[4] [1]〜[3]のいずれかの液状組成物が入れられた、容器詰飲料。
[5] [1]又は[2]の液状組成物を含む、二日酔いの症状の抑制剤。
[6] 二日酔いの症状が頭重感、吐き気、倦怠感、アルコール残り感、及び/又は、胃の不快感である、[5]の抑制剤。
That is, the present invention has the following features.
[1] A liquid composition containing bisaclone and a turmeric pigment and having a pH in the range of 2.3 or more and less than 3.2, and containing 0.15 mg or more of bisaclone per oral intake.
[2] The liquid composition according to [1], wherein bisaclone is derived from a turmeric extract.
[3] The liquid composition according to [1] or [2], which is a food or drink or a medicine.
[4] A packaged beverage containing the liquid composition according to any one of [1] to [3].
[5] An inhibitor of a hangover symptom comprising the liquid composition of [1] or [2].
[6] The inhibitor of [5], wherein the symptoms of hangover are head sensation, nausea, malaise, feeling of remaining alcohol, and / or stomach discomfort.
本発明によれば、天然化合物を有効成分とする、二日酔いの症状を抑制することが可能な組成物を提供することができる。 ADVANTAGE OF THE INVENTION According to this invention, the composition which can suppress the symptom of a hangover which uses a natural compound as an active ingredient can be provided.
1.ビサクロン
本発明において「ビサクロン」とは、ビサボラン型セスキテルペン類に分類される化合物であり、下記の平面構造式を有する化合物又はその塩を意味する。ビサクロンは平面構造式中*印で示した位置に不斉炭素を有し、そのため数種の光学異性体が存在するが、本明細書におけるビサクロンとはそのいずれの光学異性体も包含する概念である。
1. Bisacron In the present invention, “bisaclone” is a compound classified as a bisaborane-type sesquiterpene, and means a compound having the following planar structural formula or a salt thereof. Bisaclone has an asymmetric carbon at the position indicated by * in the planar structural formula, and therefore there are several kinds of optical isomers. Bisaclone in this specification is a concept that includes any optical isomers. is there.
ビサクロンは植物原料から抽出又は精製したものであってもよいし、人為的に合成されたものであってもよいが、安全性の観点から植物原料から抽出又は分離/精製したものを用いることが好ましい。 Bisacron may be extracted or purified from plant materials or artificially synthesized, but from the viewpoint of safety, it may be extracted or separated / purified from plant materials. preferable.
前記植物原料としては、ショウガ科植物が好ましく、特にCurcuma longa(ウコン)、Curcuma aromatica、Curcuma zedoaria、Curcuma phaeocaulis、Curcuma kwangsiensis、Curcuma wenyujin、Curcuma xanthorrhizaが好ましい。植物原料の根茎等の適当な部位を原型のまま、あるいは適当な寸法又は形状にカットした形態で、あるいは粉砕物の形態で、ビサクロンの製造のための原料として使用することができる。これらの原料は適宜乾燥されたものであってよい。 The plant raw material is preferably a ginger family plant, particularly preferably Curcuma longa (Curcuma), Curcuma aromatica, Curcuma zedoaria, Curcuma phaeocaulis, Curcuma kwangsiensis, Curcuma wenyujin, Curcuma xanthorrhiza. Appropriate parts such as rhizomes of plant raw materials can be used as raw materials for the manufacture of bisaclone in the original form, in a form cut into an appropriate size or shape, or in the form of a pulverized product. These raw materials may be appropriately dried.
植物原料からのビサクロンの抽出方法は特に限定されない。例えば、水、エタノール、メタノール、イソプロパノール、プロピレングリコール、ジエチルエーテル、石油エーテル、ヘキサン、アセトン、アセトニトリル、酢酸エチル、動植物油脂、又はそれらの溶媒の2種以上の混合物等の、ビサクロンを溶解可能な溶媒を用いて、植物原料から溶媒可溶性成分を抽出する。抽出溶媒としては、アルコールや水が好ましい。アルコールとしてはエタノールが好ましい。アルコールと水を混合して用いる場合の混合比は特に限定されないが、例えば重量比で10:90〜90:10の範囲が好ましく、20:80〜50:50の範囲がより好ましい。 The extraction method of bisaclone from plant materials is not particularly limited. For example, a solvent capable of dissolving bisaclone such as water, ethanol, methanol, isopropanol, propylene glycol, diethyl ether, petroleum ether, hexane, acetone, acetonitrile, ethyl acetate, animal and vegetable fats and oils, or a mixture of two or more thereof. Is used to extract solvent-soluble components from plant materials. As the extraction solvent, alcohol or water is preferable. Ethanol is preferred as the alcohol. The mixing ratio when using a mixture of alcohol and water is not particularly limited, but for example, the weight ratio is preferably in the range of 10:90 to 90:10, and more preferably in the range of 20:80 to 50:50.
得られた植物原料の抽出物を必要に応じてさらに、溶媒分画、クロマトグラフィー(カラムクロマトグラフィー、高速液体クロマトグラフィー(HPLC)等)及び/又は再結晶等の精製手段に付して、ビサクロンを分離又は精製してもよい。例えば、ビサクロンはウコンを植物原料とするメタノール抽出物を得て、当該抽出物をシリカゲルカラムでメタノール及びクロロホルムを用いて溶出させ、クルクミノイド(クルクミン、デメトキシクルクミン、ビスデメトキシクルクミンの混合物)よりも高極性の画分より分取用HPLCカラムを用いて分離又は精製することができる。 The obtained plant raw material extract is further subjected to purification means such as solvent fractionation, chromatography (column chromatography, high performance liquid chromatography (HPLC), etc.) and / or recrystallization, if necessary, and bisaclone May be separated or purified. For example, bisaclone obtains a methanol extract of turmeric as a plant raw material, elutes the extract with a silica gel column using methanol and chloroform, and more than curcuminoids (mixture of curcumin, demethoxycurcumin, bisdemethoxycurcumin) It can be separated or purified from the highly polar fraction using a preparative HPLC column.
本発明の液状組成物又は二日酔いの症状の抑制剤中には、好ましくは一回の経口摂取量当たり、ビサクロンを0.15mg以上配合する。ビサクロンは植物原料の抽出物の形態であってもよい。すなわち、本発明の液状組成物又は二日酔いの症状の抑制剤中には、一回の経口摂取量当たり、ビサクロンを0.15mg以上含有する、上記抽出溶媒を用いて得られた植物原料の抽出物を含めることができる。あるいは、ビサクロンは、植物原料の抽出物より分離/精製された形態であってもよい。 In the liquid composition of the present invention or the hangover symptom suppressor, 0.15 mg or more of bisaclone is preferably added per one oral intake. Bisaclone may be in the form of an extract of plant material. That is, the liquid composition of the present invention or the hangover symptom suppressant contains an extract of a plant raw material obtained by using the above extraction solvent, containing 0.15 mg or more of bisaclone per oral intake. Can be included. Alternatively, bisaclone may be in a form separated / purified from an extract of plant material.
なお、液状組成物中のビサクロンの量は、液状組成物を酢酸エチルと混合し、遠心分離して得られた上澄み液から酢酸エチルを減圧留去後、アセトニトリルに溶解した液を分析サンプルとして、高速液体クロマトグラフィー(HPLC)に付すことにより求めることができる。 In addition, the amount of bisaclone in the liquid composition is obtained by mixing the liquid composition with ethyl acetate and centrifuging the ethyl acetate from the supernatant obtained by centrifuging, and then using the liquid dissolved in acetonitrile as an analysis sample. It can obtain | require by attaching | subjecting to a high performance liquid chromatography (HPLC).
本発明において「一回の経口摂取量」とは、本発明の液状組成物又は二日酔いの症状の抑制剤が一度に経口摂取される量、あるいは短い時間間隔(例えば10分以下、好ましくは5分以下の時間)をおいて連続的に複数回で経口摂取される総量を意味する。本発明の液状組成物又は二日酔いの症状の抑制剤の一回の経口摂取量とは、例えば50ml〜500ml(典型的には50ml、100ml、150ml、200ml、250ml、300ml、350ml、400ml、450ml又は500ml)が挙げられる。以下でも「一回の経口摂取量」をこの意味で用いる。 In the present invention, the term “single oral intake” means the amount of the liquid composition of the present invention or the hangover symptom suppressor that is orally ingested at a time, or a short time interval (for example, 10 minutes or less, preferably 5 minutes). It means the total amount that is orally ingested several times continuously over the following time). The single oral intake of the liquid composition or the hangover symptoms inhibitor of the present invention is, for example, 50 ml to 500 ml (typically 50 ml, 100 ml, 150 ml, 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml or 500ml). Hereinafter, “single oral intake” is used in this sense.
また、本発明において「ビサクロンを0.15mg以上」とは、本発明の液状組成物又は二日酔いの症状の抑制剤の製造完了時、すなわち、本発明の液状組成物又は二日酔いの症状の抑制剤が完成製品として製造工場を出荷される段階において、「ビサクロンを0.15mg以上」含有していることを意味する。 Further, in the present invention, `` bisaclone 0.15 mg or more '' means that when the production of the liquid composition of the present invention or the hangover symptom suppressor is completed, that is, the liquid composition of the present invention or the hangover symptom suppressor is completed. It means that it contains “0.15mg or more of bisaclone” at the stage of shipping the manufacturing factory as a product.
2.ウコン色素
ウコン色素は、ウコンの根茎部分より、温時エタノールで、熱時油脂若しくはプロピレングリコールで、又は室温時〜熱時ヘキサン若しくはアセトンで抽出して得られるものであり、このようにして得られたウコン色素は主にクルクミンを含む。本発明のビサクロン含有飲料におけるウコン色素の量は一回の経口摂取量当たり、クルクミンが3mg〜50mg、より好ましくは5mg〜40mgとなる量のウコン色素が配合されるのがよい。
2. Turmeric pigment Turmeric pigment is obtained by extracting from the rhizome part of turmeric with hot ethanol, hot oil or propylene glycol, or room temperature to hot hexane or acetone. Turmeric pigments mainly contain curcumin. The amount of turmeric pigment in the bisaclone-containing beverage of the present invention is preferably blended with an amount of turmeric pigment that makes curcumin 3 mg to 50 mg, more preferably 5 mg to 40 mg per oral intake.
ウコン色素は微粒子化されたものを用いても良い。ウコン色素の微粒子化は、例えば以下のような方法により、所望の微粒子サイズが得られるように粉砕処理(微粒子化処理)して行うことができる。 Turmeric pigments may be finely divided. Turmeric pigments can be microparticulated by, for example, pulverization (micronization) so as to obtain a desired microparticle size by the following method.
微粒子化処理方法としては、水難溶性物質の微粒子化処理方法として公知の方法を用いることができる。例えば、ウコン色素を親水性有機溶媒に溶解させた溶液を水系溶媒中に分散させて微粒子化する方法や、ウコン色素を、乳化剤と混合した混合物を粉砕処理することにより、或いは、ウコン色素を乳化剤、多糖類等を含む水系溶媒中に分散させて得た分散液を粉砕処理することにより微粒子化する方法等が挙げられる(特開2005-328839号公報、特開2004-208555号公報、特開2009−201371号公報、特開2009-263638号公報)。 As the fine particle treatment method, a known method can be used as a fine particle treatment method for a poorly water-soluble substance. For example, a method in which a solution obtained by dissolving a turmeric dye in a hydrophilic organic solvent is dispersed in an aqueous solvent to form fine particles, a mixture obtained by mixing a turmeric dye with an emulsifier is pulverized, or a turmeric dye is used as an emulsifier. And a method of pulverizing a dispersion obtained by dispersing in a water-based solvent containing a polysaccharide or the like (JP 2005-328839, JP 2004-208555, JP, etc.). 2009-201371, JP 2009-263638).
微粒子化されたウコン色素は、好ましくは以下の特徴(i)及び(ii)の少なくとも一方、より好ましくは両方を備える。
(i)中心粒子径(メジアン径:d50)が16μm未満、15μm未満、14μm未満、13μm未満、12μm未満、11μm未満、10μm未満、9μm未満、8μm未満、7μm未満、6μm未満、5μm未満、4μm未満、3μm未満、2μm未満、又は、1μm未満とすることができる。上記中心粒子径の下限は任意であるが、0.2μm以上、0.3μm以上、0.4μm以上、0.5μm以上、0.6μm以上、0.7μm以上、又は、0.8μm以上とすることができる。
(ii)粒径10μm以上の粒子の分布率が50%未満、あるいは、好ましくは40%以下、30%以下、20%以下、又は15%以下である。
The micronized turmeric pigment preferably comprises at least one of the following features (i) and (ii), more preferably both.
(I) The center particle size (median diameter: d50) is less than 16 μm, less than 15 μm, less than 14 μm, less than 13 μm, less than 12 μm, less than 11 μm, less than 10 μm, less than 9 μm, less than 8 μm, less than 7 μm, less than 6 μm, less than 5 μm, 4 μm Or less, less than 3 μm, less than 2 μm, or less than 1 μm. The lower limit of the central particle diameter is arbitrary, but can be 0.2 μm or more, 0.3 μm or more, 0.4 μm or more, 0.5 μm or more, 0.6 μm or more, 0.7 μm or more, or 0.8 μm or more.
(Ii) The distribution ratio of particles having a particle size of 10 μm or more is less than 50%, or preferably 40% or less, 30% or less, 20% or less, or 15% or less.
微粒子化されたウコン抽出物の中心粒子径(メジアン径)は、水溶液中の粒子についてレーザー回折/散乱式粒子径分布測定装置LA-950V2(株式会社堀場製作所製)を用いて測定することができる(条件;屈折率:1.60、測定範囲:0.001〜3000μm、粒子径基準:体積)。 The center particle diameter (median diameter) of the finely divided turmeric extract can be measured for particles in an aqueous solution using a laser diffraction / scattering particle size distribution measuring apparatus LA-950V2 (manufactured by Horiba, Ltd.). (Condition; refractive index: 1.60, measurement range: 0.001 to 3000 μm, particle diameter standard: volume).
3.他の成分
本発明の液状組成物又は二日酔いの症状の抑制剤には、飲食品、医薬品などの最終的な形態において許容される成分であって、経口摂取可能な成分を含めることができる。
3. Other Components The liquid composition of the present invention or the hangover symptom suppressor can be an ingredient that is acceptable in the final form of foods and drinks, pharmaceuticals, etc. and can be taken orally.
このような成分としては例えば、甘味料、酸味料、ビタミン類、ミネラル類、増粘剤、乳化剤、酸化防止剤などが挙げられる。また、必要により、色素、香料、保存料、防腐剤、防かび剤などを添加してもよい。 Examples of such components include sweeteners, acidulants, vitamins, minerals, thickeners, emulsifiers, antioxidants and the like. Moreover, you may add a pigment | dye, a fragrance | flavor, a preservative, an antiseptic | preservative, a fungicide, etc. as needed.
甘味料としては、ブドウ糖、果糖、ショ糖、乳糖、麦芽糖、パラチノース、トレハロース、キシロース等の単糖や二糖、異性化糖(ブドウ糖果糖液糖、果糖ブドウ糖液糖、砂糖混合異性化糖等)、糖アルコール(エリスリトール、キシリトール、ラクチトール、パラチニット、ソルビトール、還元水飴等)、はちみつ、高甘味度甘味料(スクラロース、アセスルファムカリウム、ソーマチン、ステビア、アスパルテーム等)などが挙げられる。 Sweeteners include monosaccharides and disaccharides such as glucose, fructose, sucrose, lactose, maltose, palatinose, trehalose, and xylose, isomerized sugar (glucose fructose liquid sugar, fructose glucose liquid sugar, sugar mixed isomerized sugar, etc.) Sugar alcohols (erythritol, xylitol, lactitol, palatinit, sorbitol, reduced starch syrup, etc.), honey, high-intensity sweeteners (sucralose, acesulfame potassium, thaumatin, stevia, aspartame, etc.).
酸味料としては、下記「5.pH」に記載のものが挙げられる。
ビタミン類としては、ビタミンA、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンE、ナイアシン、イノシトールなどが挙げられる。
Examples of the sour agent include those described in “5. pH” below.
Examples of vitamins include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin E, niacin, inositol, and the like.
ミネラル類としては、カルシウム、マグネシウム、亜鉛、鉄などが挙げられる。
増粘剤としては、カラギーナン、ジェランガム、キサンタンガム、アラビアガム、タマリンドガム、グアーガム、ローカストビーンガム、カラヤガム、寒天、ゼラチン、ペクチン、大豆多糖類、カルボキシメチルセルロース(CMC)等が挙げられる。
Examples of minerals include calcium, magnesium, zinc, iron and the like.
Examples of the thickener include carrageenan, gellan gum, xanthan gum, gum arabic, tamarind gum, guar gum, locust bean gum, karaya gum, agar, gelatin, pectin, soybean polysaccharide, carboxymethylcellulose (CMC) and the like.
乳化剤としては、グリセリン脂肪酸エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エステル、レシチン、植物性ステロール、サポニン等が挙げられる。
酸化防止剤としては、ビタミンC、トコフェロール(ビタミンE)、酵素処理ルチン、カテキン等が挙げられる。
Examples of the emulsifier include glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, lecithin, vegetable sterol, saponin and the like.
Examples of the antioxidant include vitamin C, tocopherol (vitamin E), enzyme-treated rutin, catechin and the like.
これらの成分は、それぞれ当業者が飲料等の液状組成物に通常採用する範囲内の量で適宜配合することができる。 Each of these components can be appropriately blended in an amount within the range usually employed by those skilled in the art for liquid compositions such as beverages.
また、本発明の液状組成物又は二日酔いの症状の抑制剤には、二日酔いの症状の抑制に有効である公知の成分(例えば、肝臓加水分解物、アラニン等)を含めることができる。 In addition, the liquid composition or the hangover symptom inhibitor of the present invention may contain known components (for example, liver hydrolyzate, alanine, etc.) that are effective in suppressing the hangover symptom.
4.pH
本発明の液状組成物又は二日酔いの症状の抑制剤のpH値は、加えられる酸味料の量を適宜調節することにより調節することができる。本発明の液状組成物又は二日酔いの症状の抑制剤のpH値は、飲料として一般的なpH値(例えばpH2.3〜7.5程度)から適宜選択することが可能である。好ましくは本発明の液状組成物又は二日酔いの症状の抑制剤のpH値は2.9以上、3.2未満の範囲にある。本発明の液状組成物又は二日酔いの症状の抑制剤のpH値を前記範囲に設定することによって、植物原料の抽出物に起因する、「苦味」や「渋み」等の不快な呈味を抑制することができる。なお、本発明においてpH値は品温20℃で測定された値を指す。
4). pH
The pH value of the liquid composition of the present invention or the hangover symptom inhibitor can be adjusted by appropriately adjusting the amount of acidulant added. The pH value of the liquid composition of the present invention or the hangover symptom suppressor can be appropriately selected from pH values generally used for beverages (for example, about pH 2.3 to 7.5). Preferably, the pH value of the liquid composition or the hangover symptoms inhibitor of the present invention is in the range of 2.9 or more and less than 3.2. By setting the pH value of the liquid composition of the present invention or the hangover symptom suppressor within the above range, unpleasant taste such as “bitterness” and “astringency” due to the extract of the plant material is suppressed. be able to. In the present invention, the pH value refers to a value measured at a product temperature of 20 ° C.
pH値の調整に用いられる酸味料としては飲料の製造に一般的に利用されるものが挙げられ、例えばクエン酸、リンゴ酸、グルコン酸、酒石酸、乳酸、リン酸、又はこれらの塩等があり、これらのうちの1種又は2種以上を利用することができる。 Examples of acidulants used to adjust the pH value include those commonly used in beverage production, such as citric acid, malic acid, gluconic acid, tartaric acid, lactic acid, phosphoric acid, or salts thereof. One or more of these can be used.
5.液状組成物及びその用途
本発明の液状組成物は、アルコール摂取後の起床時のいわゆる二日酔い症状(特に、頭重感、吐き気、倦怠感、アルコール残り感、胃の不快症状)の軽減作用を有する飲食品組成物又は医薬品組成物として使用することができる。
5. Liquid composition and use thereof The liquid composition of the present invention has an action to reduce so-called hangover symptoms (especially head sensation, nausea, malaise, feeling of residual alcohol, stomach discomfort) after waking up after ingesting alcohol. It can be used as a product composition or a pharmaceutical composition.
本発明の液状組成物は、液状食品(飲料)として提供されてもよいし、液状の経口投与用の医薬品として提供されてもよいが、好ましくは飲料である。液状組成物は、水を基調とする組成物であり、上記成分を水と混合して製造することができる。各成分の配合量は上記したとおりである。かかる液状組成物は、飲料用容器として使用される容器に収容することができる。飲料用容器としてはポリエチレンテレフタレート(PET)製容器、所謂PETボトルや、金属缶容器等が挙げられる。容器の形態は特に限定されない。また、容器の容量は特に限定されないが、例えば50ml〜500ml(典型的には50ml、100ml、150ml、200ml、250ml、300ml、350ml、400ml、450ml又は500ml)、好ましくは100ml〜200mlとすることができる。液状組成物を容器に収容する手段は任意である。 The liquid composition of the present invention may be provided as a liquid food (beverage) or a liquid pharmaceutical for oral administration, but is preferably a beverage. The liquid composition is a composition based on water, and can be produced by mixing the above components with water. The amount of each component is as described above. Such a liquid composition can be contained in a container used as a beverage container. Examples of beverage containers include polyethylene terephthalate (PET) containers, so-called PET bottles, metal can containers, and the like. The form of the container is not particularly limited. Further, the capacity of the container is not particularly limited, but for example, 50 ml to 500 ml (typically 50 ml, 100 ml, 150 ml, 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml or 500 ml), preferably 100 ml to 200 ml. it can. The means for accommodating the liquid composition in the container is arbitrary.
I.血中エタノール濃度に対する効果
ビサクロン及びクルクミンの血中エタノール濃度に対する効果について以下のとおり試験した。
I. Effect on blood ethanol concentration The effects of bisaclone and curcumin on blood ethanol concentration were tested as follows.
1.供試動物
各試験対象物について、7週齢のオスSDラット(8匹)を使用した。
1. Test animals For each test object, 7-week-old male SD rats (8 animals) were used.
2.試験対象物
コントロール:デキストリン(松谷化学工業株式会社)
クルクミン:ターメリックカラーHJK(稲畑香料株式会社)
ビサクロン:ウコン(Curcuma longa)の根茎部分の根茎部分を水を用いて抽出し、得られた水抽出液をメタノールにて再抽出し、得られたメタノール抽出液より分取カラムを用いて精製したものを使用した。
2. Test object control: Dextrin (Matsuya Chemical Co., Ltd.)
Curcumin: Turmeric Color HJK (Inabata Fragrance Co., Ltd.)
Bisaclon: The rhizome part of curcuma longa was extracted with water, and the resulting water extract was re-extracted with methanol, and purified from the resulting methanol extract using a preparative column. I used something.
クルクミン及びビサクロンは、0.5w/v%メチルセルロース(和光純薬工業)(以下、「0.5%MC」と記載する)に溶解した。 Curcumin and bisaclone were dissolved in 0.5 w / v% methylcellulose (Wako Pure Chemical Industries) (hereinafter referred to as “0.5% MC”).
3.試験方法
供試動物入荷時より本飼育開始前日まで1週間、予備飼育を行い馴化した。
3. Test method Preliminary breeding was acclimatized for one week from the arrival of the test animals to the day before the start of the breeding.
試験対象物は胃ゾンデを用いて下記投与量となるように強制胃内投与した。エタノールは下記投与量となるように、同時に同じ経路で投与した。
クルクミンのみ:125mg/kg
クルクミン+ビサクロン:クルクミン125mg/kg+ビサクロン20mg/kg
エタノール:2g/kg
The test object was forcibly administered intragastrically using a gastric sonde to the following dosage. Ethanol was administered by the same route at the same time so that the following dose was obtained.
Curcumin only: 125mg / kg
Curcumin + bisaclone: Curcumin 125mg / kg + bisaclone 20mg / kg
Ethanol: 2g / kg
エタノール投与後、10、30、60、120、180、240分時に尾静脈よりヘパリン加採血を行い、F−キット エタノール(J.K.インターナショナル)を製造元の指示書に従い、各時点の血中エタノール濃度を測定した。 After ethanol administration, heparinized blood is collected from the tail vein at 10, 30, 60, 120, 180, and 240 minutes, and F-kit ethanol (JK International) is measured according to the manufacturer's instructions to measure the blood ethanol concentration at each time point. did.
4.試験結果
結果を図1に示す。各結果は各時点の血中濃度-時間曲線下面積(AUC)の合計をそれぞれ示す。クルクミンを単独で投与するよりも、クルクミン及びビサクロンの混合物を投与することにより、血中エタノール濃度をより低下できることが確認された。
4). Test results The results are shown in FIG. Each result shows the total area under the blood concentration-time curve (AUC) at each time point. It was confirmed that the ethanol concentration in blood can be further reduced by administering a mixture of curcumin and bisaclone rather than administering curcumin alone.
II.二日酔い症状に対する効果
ビサクロンの二日酔い症状に対する効果について以下のとおり試験した。
II. Effect on hangover symptoms The effect of bisaclone on hangover symptoms was tested as follows.
1.試験飲料
ビサクロン含有試験飲料(実施例A)は、水以外の成分(粉末原料)を混合した後、水に添加溶解して100mLの水溶液とし、93℃に加熱したものを金属缶にホットパックして作製した。比較例aはホットパックした後、さらに40℃にて一週間保存した以外は、上記実施例Aと同様に作製した。各試験飲料のpH値は3.1とした。ビサクロンは酸性水溶液中、40℃にて保存することによって分解が促進され、最終的には試験飲料中のビサクロンを消失させることができる。
1. Test beverage A test beverage containing bisaclone (Example A) is prepared by mixing ingredients other than water (powder raw material), adding and dissolving in water to make a 100 mL aqueous solution, and heating it to 93 ° C in a metal can. Made. Comparative Example a was prepared in the same manner as in Example A except that it was hot-packed and then stored at 40 ° C. for one week. The pH value of each test beverage was 3.1. By keeping bisaclone in an acidic aqueous solution at 40 ° C., the decomposition is accelerated, and finally bisaclone in the test beverage can be eliminated.
ウコン色素は、ウコン(Curcuma longa)の根茎部分をアセトンを用いて抽出し、減圧してアセトンを揮発させることにより得たものである。このウコン色素には35質量%のクルクミンが含有され、各試験飲料中にはクルクミンが30mg含まれた。 The turmeric pigment is obtained by extracting the rhizome part of turmeric (Curcuma longa) with acetone and evaporating the acetone under reduced pressure. This turmeric pigment contained 35% by weight of curcumin, and each test beverage contained 30 mg of curcumin.
ビサクロンはウコン抽出物の形態で用いた。すなわち、ビサクロンを所定量含有するウコン抽出物を各試験飲料中に配合した。ウコン抽出物はウコン(Curcuma longa)の根茎部分の根茎部分を水を用いて抽出して得たものである。各試験飲料中のビサクロンの量は、試験飲料を酢酸エチルと混合し、遠心分離して得られた上澄み液から酢酸エチルを減圧留去後、アセトニトリルに溶解した液を分析サンプルとして、高速液体クロマトグラフィー(HPLC)に付すことにより求めた。HPLCは以下の条件で行った。
Bisaclone was used in the form of turmeric extract. That is, a turmeric extract containing a predetermined amount of bisaclone was blended in each test beverage. The turmeric extract is obtained by extracting the rhizome part of curcuma longa with water. The amount of bisaclone in each test beverage was determined by high-performance liquid chromatography using a solution obtained by mixing the test beverage with ethyl acetate and centrifuging the supernatant and distilling off ethyl acetate under reduced pressure and then dissolving in acetonitrile. It was determined by attaching to a graphic (HPLC). HPLC was performed under the following conditions.
実施例A及び比較例aは以下の組成を有した。ビサクロンが実施例Aには0.15mg、比較例aにはビサクロンが検出されなかった。 Example A and Comparative Example a had the following compositions. Bisaclone was 0.15 mg in Example A, and no bisaclone was detected in Comparative Example a.
2.試験対象者
試験対象者は、アルコール飲料を飲むことができる20〜65才の男女から選抜した13名とした。アルコール飲料が飲めない人(自己申告)、通院中の人、服薬中の人、腎臓・肝臓疾患に疾病のある人、各種過敏症の人は試験対象者から除外した。
2. Test subjects 13 test subjects were selected from men and women aged 20 to 65 who can drink alcoholic beverages. Those who could not drink alcoholic beverages (self-reported), those who were in the hospital, those who were taking medication, those who were ill with kidney / liver disease, and those with various hypersensitivities were excluded from the study subjects.
3.試験方法
各試験飲料について以下の手順により二日酔い抑制効果を確認した。
次の内容の試験を1週間を開けて2回実施した。
3. Test Method The hangover suppression effect was confirmed for each test beverage by the following procedure.
The following test was conducted twice in a week.
試験前日に上記実施例A又は比較例aを摂取した後、2時間にわたって食事をしながら飲酒した。個人ごとに酒量並びに食事のメニュー及び量を管理し、2回の試験ともほぼ同じ酒量及び食事条件になるようにした。 After ingesting Example A or Comparative Example a on the day before the test, alcohol was consumed while eating for 2 hours. The amount of alcohol and the menu and amount of food were managed for each individual so that the same amount of alcohol and food conditions were used in the two tests.
飲酒後に就寝し、7時間を目安として睡眠をとった。飲酒後摂取できる水の量は200mLまでとした。起床後に二日酔いに関するアンケートを行った。 I went to bed after drinking, and took 7 hours as a guide. The amount of water that can be consumed after drinking was up to 200 mL. After getting up, a questionnaire about hangover was conducted.
以下の事項は禁止した。
二日酔い改善効果のある医薬、食品の摂取
The following matters were prohibited:
Ingestion of medicines and foods to improve hangover
4.試験スケジュール
試験対象者5名に対し、実施例Aを試験飲料として摂取する前記試験(1回目の試験)を行い、次に比較例aについて前記試験(2回目の試験)を行った。また、試験対象者の残りの8名に対して比較例aを試験飲料として摂取する前記試験(1回目の試験)を行い、次に実施例Aについて前記試験(2回目の試験)を行った。
4). Test schedule The test (first test) ingesting Example A as a test beverage was performed on five test subjects, and then the test (second test) was performed on Comparative Example a. Moreover, the said test (1st test) which ingests comparative example a as a test drink was performed with respect to the remaining 8 test subjects, and the said test (2nd test) was then performed about Example A. .
5.アンケートによる評価項目
アンケートでは、各試験対象者に、頭痛、頭重感、吐き気、倦怠感、アルコール残り感、胃の不快症状の6項目についてVAS法による自己評価結果を記入させた。
5. Evaluation items by questionnaire In the questionnaire, each test subject was asked to fill in the self-evaluation results by the VAS method for six items: headache, head sensation, nausea, malaise, feeling of remaining alcohol, and stomach discomfort.
VAS (Visual Analog Scale) 法とは、自覚的症状の程度を数値化して評価する検査である。直線状に、考えられうる最高の状態を右端、最低を左端としてその線分上に自分の状態の程度を示してもらう方法である。主観的な評価のために臨床医学でも広く用いられており、特に同被験者間の投与前後の状態の比較などに使われる。 The VAS (Visual Analog Scale) method is a test that evaluates the degree of subjective symptoms by quantifying. In this method, the highest possible state is set to the right end and the lowest is set to the left end in a straight line. It is also widely used in clinical medicine for subjective evaluation, and is used especially for comparison of the condition before and after administration between subjects.
6.試験結果
各試験飲料を摂取した試験での個々の評価項目について、被験者全員のVAS記入値を集計した平均値を得た。結果を図2に示す。
6). Test result For each evaluation item in the test ingesting each test beverage, an average value was obtained by summing up the VAS entry values of all the subjects. The results are shown in FIG.
ビサクロン0.15mg及びクルクミン30mgを含有する実施例Aでは、ビサクロンを含まずクルクミン30mgを含有する比較例aと比較して、二日酔い症状である頭痛、頭重感、吐き気、倦怠感、アルコール残り感、胃の不快症状のすべての項目について抑制がみられ、特に「頭重感」や「胃の不快症状」を抑制する作用が有意に高いことが確認された。 In Example A containing 0.15 mg of bisaclone and 30 mg of curcumin, compared with Comparative Example a containing 30 mg of curcumin without bisaclone, hangover symptoms, headache, nausea, malaise, residual alcohol, stomach It was confirmed that all the items of discomfort symptoms were significantly suppressed, and in particular, the effect of suppressing “head feeling” and “stomach discomfort” was significantly high.
以上の結果より、少なくとも0.15mgのビサクロンを、クルクミンと摂取することによって、有効成分としてクルクミンのみを摂取する場合と比べて、高い二日酔い症状抑制効果を得られることが明らかとなった。 From the above results, it has been clarified that by taking at least 0.15 mg of bisaclone with curcumin, it is possible to obtain a higher hangover symptom suppression effect than in the case of taking only curcumin as an active ingredient.
すなわち、本発明は、以下の特徴を有する。
[1] ウコン色素と、一回の経口摂取量当たり0.15mg以上のビサクロンとを含有する液状組成物。
[2] ビサクロンがウコン抽出物に由来する、[1]の液状組成物。
[3] 飲食品又は医薬品である、[1]又は[2]の液状組成物。
[4] [1]〜[3]のいずれかの液状組成物が入れられた、容器詰飲料。
[5] [1]又は[2]の液状組成物を含む、二日酔いの症状の抑制剤。
[6] 二日酔いの症状が頭重感、吐き気、倦怠感、アルコール残り感、及び、胃の不快感から選択される一つ以上の症状である、[5]の抑制剤。
That is, the present invention has the following features.
[1] c Con dye and a liquid composition having containing a single or 0.15mg per oral intake Bisakuron.
[2] The liquid composition according to [1], wherein bisaclone is derived from a turmeric extract.
[3] The liquid composition according to [1] or [2], which is a food or drink or a medicine.
[4] A packaged beverage containing the liquid composition according to any one of [1] to [3].
[5] An inhibitor of a hangover symptom comprising the liquid composition of [1] or [2].
[6] symptoms Zuomo sense of hangover, nausea, fatigue, alcohol remaining feeling,及beauty, which is one or more symptoms selected from stomach discomfort, inhibitors of [5].
植物原料からのビサクロンの抽出方法は特に限定されない。例えば、水、エタノール、メタノール、イソプロパノール、プロピレングリコール、ジエチルエーテル、石油エーテル、ヘキサン、アセトン、アセトニトリル、酢酸エチル、動植物油脂、又はそれらの溶媒の2種以上の混合物等の、ビサクロンを溶解可能な溶媒を用いて、植物原料から溶媒可溶性成分を抽出する。抽出溶媒としては、アルコール等の親水性抽出溶媒及び/又は水が好ましい。アルコールとしてはエタノールが好ましい。アルコールと水を混合して用いる場合の混合比は特に限定されないが、例えば重量比で10:90〜90:10の範囲が好ましく、20:80〜50:50の範囲がより好ましい。 The extraction method of bisaclone from plant materials is not particularly limited. For example, a solvent capable of dissolving bisaclone such as water, ethanol, methanol, isopropanol, propylene glycol, diethyl ether, petroleum ether, hexane, acetone, acetonitrile, ethyl acetate, animal and vegetable fats and oils, or a mixture of two or more thereof. Is used to extract solvent-soluble components from plant materials. The extraction solvent is preferably a hydrophilic extraction solvent such as alcohol and / or water. Ethanol is preferred as the alcohol. The mixing ratio when using a mixture of alcohol and water is not particularly limited, but for example, the weight ratio is preferably in the range of 10:90 to 90:10, and more preferably in the range of 20:80 to 50:50.
また、本発明において「ビサクロンを0.15mg以上」とは、本発明の液状組成物又は二日酔いの症状の抑制剤の製造完了時、すなわち、本発明の液状組成物又は二日酔いの症状の抑制剤が完成製品として製造工場を出荷される段階において、「ビサクロンを0.15mg以上」含有していること、好ましくは本発明の液状組成物又は二日酔いの症状の抑制剤の摂取時において「ビサクロンを0.15mg以上」含有していることを意味する。 Further, in the present invention, `` bisaclone 0.15 mg or more '' means that when the production of the liquid composition of the present invention or the hangover symptom suppressor is completed, that is, the liquid composition of the present invention or the hangover symptom suppressor is completed. At the stage of shipping a manufacturing factory as a product, it contains `` bisaclone 0.15 mg or more '' , preferably `` bisaclone 0.15 mg or more '' when ingesting the liquid composition of the present invention or a hangover symptom suppressor It means that it contains .
4.pH
本発明の液状組成物又は二日酔いの症状の抑制剤のpH値は、加えられる酸味料の量を適宜調節することにより調節することができる。本発明の液状組成物又は二日酔いの症状の抑制剤のpH値は、飲料として一般的なpH値(例えばpH2.3〜7.5程度)から適宜選択することが可能である。好ましくは本発明の液状組成物又は二日酔いの症状の抑制剤のpH値は2.3以上、好ましくは2.9以上、3.2未満の範囲にある。pH値が前記範囲にある本発明の液状組成物又は二日酔いの症状の抑制剤においては、植物原料の抽出物に起因する、「苦味」や「渋み」等の不快な呈味が抑制されている。なお、本発明においてpH値は品温20℃で測定された値を指す。
4). pH
The pH value of the liquid composition of the present invention or the hangover symptom inhibitor can be adjusted by appropriately adjusting the amount of acidulant added. The pH value of the liquid composition of the present invention or the hangover symptom suppressor can be appropriately selected from pH values generally used for beverages (for example, about pH 2.3 to 7.5). Preferably, the pH value of the liquid composition of the present invention or the hangover symptom suppressor is 2.3 or more, preferably 2.9 or more and less than 3.2. In the liquid composition or hangover symptoms inhibitor of the present invention the pH value is in the range, due to extracts of plant material, unpleasant taste such as "bitter" and "bitter" is suppressed . In the present invention, the pH value refers to a value measured at a product temperature of 20 ° C.
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013205631A JP5543651B1 (en) | 2013-09-30 | 2013-09-30 | Liquid composition containing useful components in turmeric and turmeric pigment |
KR1020140130056A KR101548598B1 (en) | 2013-09-30 | 2014-09-29 | Liquid compositions containing the component of turmeric and turmeric dye |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013205631A JP5543651B1 (en) | 2013-09-30 | 2013-09-30 | Liquid composition containing useful components in turmeric and turmeric pigment |
Publications (2)
Publication Number | Publication Date |
---|---|
JP5543651B1 JP5543651B1 (en) | 2014-07-09 |
JP2015067593A true JP2015067593A (en) | 2015-04-13 |
Family
ID=51409519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013205631A Active JP5543651B1 (en) | 2013-09-30 | 2013-09-30 | Liquid composition containing useful components in turmeric and turmeric pigment |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5543651B1 (en) |
KR (1) | KR101548598B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019019061A (en) * | 2017-07-12 | 2019-02-07 | ライオン株式会社 | Oral liquid pharmaceutical composition and pharmaceutical |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101601947B1 (en) * | 2015-06-03 | 2016-03-09 | 주식회사 한생바이오 | Beverage composition for relieving hangover comprising peanut sprouts and manufacturing method thereof |
JP6773362B2 (en) * | 2015-10-30 | 2020-10-21 | ハウスウェルネスフーズ株式会社 | Skin moisturizer for ingestion or administration |
KR102485101B1 (en) * | 2017-10-31 | 2023-01-04 | 하우스 쇼쿠힝 그룹 혼샤 가부시키가이샤 | Bisacron Extraction Method |
KR102030560B1 (en) * | 2019-09-02 | 2019-10-10 | 권오직 | Liquefied type health supplement food using curcuma domestica and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006022056A (en) * | 2004-07-08 | 2006-01-26 | I M B Kk | Agent for preventing getting drunk |
JP2011068569A (en) * | 2009-09-24 | 2011-04-07 | House Foods Corp | Composition containing curcuma longa extract and curcuma zedoaria extract |
JP2011250707A (en) * | 2010-05-31 | 2011-12-15 | House Foods Corp | Packaged turmeric beverage |
JP2011250709A (en) * | 2010-05-31 | 2011-12-15 | House Foods Corp | Packaged turmeric beverage |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103100028A (en) | 2011-11-14 | 2013-05-15 | 甘肃创兴生物工程有限责任公司 | Soft capsule favorable for reducing alcoholic liver injury and preparation method thereof |
-
2013
- 2013-09-30 JP JP2013205631A patent/JP5543651B1/en active Active
-
2014
- 2014-09-29 KR KR1020140130056A patent/KR101548598B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006022056A (en) * | 2004-07-08 | 2006-01-26 | I M B Kk | Agent for preventing getting drunk |
JP2011068569A (en) * | 2009-09-24 | 2011-04-07 | House Foods Corp | Composition containing curcuma longa extract and curcuma zedoaria extract |
JP2011250707A (en) * | 2010-05-31 | 2011-12-15 | House Foods Corp | Packaged turmeric beverage |
JP2011250709A (en) * | 2010-05-31 | 2011-12-15 | House Foods Corp | Packaged turmeric beverage |
Non-Patent Citations (3)
Title |
---|
JPN6014002177; Journal of Asian Natural Products Research, 2009, Vol.11, No.6, p.569-575 * |
JPN6014002179; Acta Pharmaceutica Sinica, 2008, Vol.43, No.7, p.724-727 * |
JPN6014002180; International Immunopharmacology, 2008, Vol.8, p.1272-1281 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019019061A (en) * | 2017-07-12 | 2019-02-07 | ライオン株式会社 | Oral liquid pharmaceutical composition and pharmaceutical |
JP7095235B2 (en) | 2017-07-12 | 2022-07-05 | ライオン株式会社 | Oral liquid pharmaceutical compositions and pharmaceuticals |
Also Published As
Publication number | Publication date |
---|---|
KR20150037611A (en) | 2015-04-08 |
JP5543651B1 (en) | 2014-07-09 |
KR101548598B1 (en) | 2015-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011037099A1 (en) | Composition comprising curcuma longa extract together with curcuma zedoaria extract | |
JP5543651B1 (en) | Liquid composition containing useful components in turmeric and turmeric pigment | |
KR102445766B1 (en) | Oil-in-water emulsion composition and food and beverage containing same | |
JP6773361B2 (en) | Mood condition improver | |
JP2019019142A (en) | Inhibitors of vcam-1 expression | |
JP5415360B2 (en) | Container turmeric beverage | |
JP5543656B1 (en) | Composition containing useful ingredients in turmeric | |
JP5759047B1 (en) | Low moisture composition containing useful ingredients in turmeric | |
JP5572775B1 (en) | Low moisture composition containing useful ingredients in turmeric | |
TW201434470A (en) | Nutritional compositions and methods for enhancing cognitive function and muscle function | |
US20180125795A1 (en) | Cinnamaldehyde compositions and methods | |
JP5543655B1 (en) | Beverages that stably contain useful ingredients in turmeric | |
JP2011510016A (en) | Combination therapy composed of actinidia and steroids and their use | |
US20230033276A1 (en) | Active ingredient-containing nanoemulsions | |
US20100003351A1 (en) | Compositions comprising rhodiola rosea and methods of use thereof | |
WO2021002334A1 (en) | COMPOSITION FOR INHIBITING TNF-α OR IL-6 PRODUCTION | |
JP5543652B1 (en) | Method for producing a beverage containing useful ingredients in turmeric | |
JP5700956B2 (en) | Container turmeric beverage | |
JP6835396B2 (en) | Composition for reducing blood glucose concentration, reducing blood hemoglobin A1c amount, or increasing blood HDL-cholesterol level | |
JP7452777B2 (en) | Compositions for improving or maintaining quality of life | |
JP7452776B2 (en) | Composition for lowering blood pressure | |
WO2019203338A1 (en) | Composition containing turmeronol a and/or turmeronol b | |
JP6261263B2 (en) | Turmeric extract-containing beverage | |
JP2022107111A (en) | Agent for prevention or treatment of mood disorder | |
WO2020008359A1 (en) | A formulation for the prevention and as a coadjuvant treatment of neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140408 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140508 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5543651 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |